Anthera Pharma (ANTH) Says Pre-Specified Primary Endpoint Wasn't Met in Phase2b PEARL-SC Dose Ranging Study of Blisibimod

Go back to Anthera Pharma (ANTH) Says Pre-Specified Primary Endpoint Wasn't Met in Phase2b PEARL-SC Dose Ranging Study of Blisibimod